- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06694740
Wirkung von Interferon Gamma als Behandlung für postaggressive Immunsuppression auf Intensivstationen, eine randomisierte bayesianische doppelblinde kontrollierte Studie im Vergleich zu Placebo (INFINITY)
The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation. Recently, the existence of a common immune response pattern to acute aggression has been demonstrated, and with it the existence of a phenomenon known as post-aggressive immunosuppression (PAIS).
This immunological adaptation, initially implemented as a host defense mechanism to protect against an overwhelming systemic reaction, can, if prolonged, lead to multiple complications resulting in significant delayed morbidity and mortality. Diagnosis is based on the use of immuno-inflammatory biomarkers, the most widely studied of which is monocyte expression of major histocompatibility complex type II molecules (mHLA-DR).
We have recently confirmed that PAIS can affect all types of patients admitted to the intensive care unit, but mainly occurs in the most severe patients. We also showed that the occurrence of PAIS was strongly associated with the subsequent occurrence of secondary infection and excess mortality.
Currently, there is no treatment with proven efficacy for PAIS, but several drugs have been shown to restore leukocyte function in-vitro. Several teams have reported the use of immunostimulatory molecules in patients with treatment failure, with a good safety profile and encouraging results. We believe that earlier treatment of patients with proven PAIS could improve their clinical outcome.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Charles De ROQUETAILLADE, MD
- Telefonnummer: +33 01 49 95 55 68
- E-Mail: charles.de-roquetaillade@aphp.fr
Studieren Sie die Kontaktsicherung
- Name: Benjamin CHOUSTERMAN, Professor
- Telefonnummer: +33 01 49 95 85 18
- E-Mail: benjamin.chousterman@aphp.fr
Studienorte
-
-
-
Limoges, Frankreich, 87000
- Rekrutierung
- Dr Francois Bruno
-
Kontakt:
- Bruno Francois, MD
- Telefonnummer: +33 05 55 05 88 41
- E-Mail: bruno.françois@chu-limoges.fr
-
Nancy, Frankreich
- Rekrutierung
- Pr Antoine Kimmoun
-
Kontakt:
- Antoine Kimmoun, Professor
- Telefonnummer: +33 03 83 85 14 95
- E-Mail: a.kimmoun@chru-nancy.fr
-
Paris, Frankreich
- Rekrutierung
- Pr Dépret
-
Kontakt:
- Pr Dépret François, Professor
- Telefonnummer: +33 01 42 49 95 70
- E-Mail: francois.depret@aphp.fr
-
Paris, Frankreich, 75010
- Rekrutierung
- Pr Benjamin Chousterman
-
Kontakt:
- Chousterman Benjamin, Professor
- Telefonnummer: +33 0149958518
- E-Mail: benjamin.chousterman@aphp.fr
-
Paris, Frankreich, 75013
- Rekrutierung
- Pr Constantin Michel
-
Kontakt:
- Michel Constantin, Professor
- Telefonnummer: +33 01 42 16 22 59
- E-Mail: Jean-michel.constantin@aphp.fr
-
Paris, Frankreich
- Rekrutierung
- Pr Megarbane
-
Kontakt:
- Bruno Megarbane, Professor
- Telefonnummer: +33 01 49 95 84 42
- E-Mail: Bruno.megarbane@aphp.fr
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patient ≥ 18 years old
- SOFA score for first 24 hours post-admission ≥ 6
- Mechanically ventilated at the time of inclusion (non-invasive ventilation (NIV) and high-flow nasal oxygen excluded)
- mHLA-DR< 8,000 AB/C measured between the 5th and 10th day after admission to the intensive care unit
- Patient affiliated to a social security scheme
- Written informed consent from a parent, relative or trusted person. If there is no parent, relative or trusted person, the patient may be included under an emergency procedure and consent to continue will be obtained as soon as possible
Exclusion Criteria:
- Patient with estimated life expectancy of less than 3 months
- Patients with a predicted remaining stay in intensive care < 72 hours
- Patients with an expected prolonged duration of mechanical ventilation: comatose or vegetative patients (admission for severe stroke with Glasgow score < 8, patient resuscitated from an arterial stroke,) patients with tracheotomy for ENT problems, patients suffering from muscular disease (e.g. myopathy), patients on long-term mechanical ventilation
- Pregnant or breast-feeding women
- Contraindication of Imukin (hypersensitivity to interferon gamma-1b or known hypersensitivity to related products, such as another interferon)
- Patients on immunosuppressive therapy, including long-term corticosteroid therapy (>2.5mg/d prednisone equivalent)
- Patients with preexisting severe hepatic( Grade C cirrhosis ) or preexisting kidney failure requiring dialysis
- Patient included in another interventional study (excluding RIPH2 cases not involving prolonged mechanical ventilation)
- People under court protection and protected adults
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: interferon gamma-1b injection
Patients randomized to the experimental arm will receive : Recombinant human interferon gamma-1b 2 X 106 IU, injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections) |
|
|
Placebo-Komparator: Placebo injection
Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections) |
Patients randomized to the placebo arm will receive saline injectable solution. Subcutaneous injection every 24 hours for 3 consecutive days (3 total injections) |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
number of days alive without mechanical ventilation
Zeitfenster: on Day 28 after drug administration
|
number of days alive without mechanical ventilation on day 28 after randomization or on discharge from intensive care if this occurs before the 28th day |
on Day 28 after drug administration
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Evaluate the efficacy of IFNy in correcting PAIS-defining biological abnormalities (re-ascension of mHLA-DR above 8,000 AB/C) between patients treated with recombinant interferon gamma 1-b versus placebo
Zeitfenster: Day 1 to Day 7 and at Day 28 post randomization
|
Evolution of mHLA-DR measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo. |
Day 1 to Day 7 and at Day 28 post randomization
|
|
Evaluate, depending on the randomization arm, the kinetics of plasma inflammatory parameters between patients treated with recombinant interferon gamma 1-b versus placebo
Zeitfenster: Day 0, Day 3 and at Day 7 post randomization
|
Evolution of inflammation markers (IL-1, IL-2, IL-6, IL-8, TNFa, etc.) measured in plasma at Day 0, Day 3 and Day 7, or at discharge from intensive care if it occurs before (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 0, Day 3 and at Day 7 post randomization
|
|
mortality at Day 28 and Day 90 after randomization
Zeitfenster: Day 28 and Day 90 after randomization
|
Mortality rate at Day 28 and Day 90 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 28 and Day 90 after randomization
|
|
incidence of nosocomial infections during intensive care unit stay
Zeitfenster: from Day 0 to Day 28 (or the discharge from intensive care)
|
The incidence of nosocomial infections during an ICU stay between patients treated with recombinant interferon gamma 1-b versus placebo |
from Day 0 to Day 28 (or the discharge from intensive care)
|
|
number of days alive whithout antibiotic
Zeitfenster: Day 28 after drug administration
|
Number of days alive without antibiotic assessed on day 28 after randomization between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 28 after drug administration
|
|
length of stay in intensive care between patients
Zeitfenster: from Day 0 to Day 28 (or the discharge from intensive care)
|
Number of days in intensive care between patients treated with recombinant interferon gamma 1-b versus placebo |
from Day 0 to Day 28 (or the discharge from intensive care)
|
|
- Compare organ failure score (SOFA) kinetics between patients treated with recombinant interferon gamma 1-b versus placebo
Zeitfenster: From inclusion to Day 7
|
Kinetics of SOFA score assessed at inclusion and during the 7 days following inclusion between patients treated with recombinant interferon gamma 1-b versus placebo |
From inclusion to Day 7
|
|
Evaluate, depending on the randomization arm, the transcriptomic profile of circulating peripheral blood mononuclear cells count between patients treated with recombinant interferon gamma 1-b versus placebo
Zeitfenster: Day 0, Day 3 and Day 7 after randomization
|
Evolution of the transcriptomic profile of circulating peripheral blood mononuclear cells (PBMCs) using scRNAseq analysis measured at Day 0, Day 3 and Day 7 or upon discharge from intensive care if this occurs earlier. |
Day 0, Day 3 and Day 7 after randomization
|
|
Evaluate, depending on the randomization arm the leucocyte count between patients treated with recombinant interferon gamma 1-b versus placebo
Zeitfenster: Day 0 to Day 7 and at Day 28 post randomization
|
Evolution and kenetics of the leucocyte count measured at Day 0, Day 1, Day 2, Day 3, Day 7 and Day 28 or at discharge from intensive care if earlier (Day 0 corresponding to the day of inclusion in the study) between patients treated with recombinant interferon gamma 1-b versus placebo |
Day 0 to Day 7 and at Day 28 post randomization
|
Mitarbeiter und Ermittler
Ermittler
- Studienstuhl: Benjamin Chousterman, Professor, APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Infektionen
- Systemisches Entzündungsreaktionssyndrom
- Entzündung
- Pathologische Zustände, Anzeichen und Symptome
- Sepsis
- Peptide
- Aminosäuren, Peptide und Proteine
- Proteine
- Biologische Faktoren
- Interzelluläre Signalpeptide und Proteine
- Zytokine
- Interferonen
- Lymphokine
- Makrophagen-aktivierende Faktoren
- Interferon-Gamma
Andere Studien-ID-Nummern
- APHP220672
- 2023-506725-11-00 (Ctis)
- 2023 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .